A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia
Clinical trial NCT01256073 · COMPLETED
Trial details
- NCT number
- NCT01256073
- Sponsor
- Innate Pharma
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2007-02-01
- Primary completion
- 2013-07-01
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.